<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Recently, several drugs have been shown to exert beneficial effects for <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> through mild regulation of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> function </plain></SENT>
<SENT sid="1" pm="."><plain>Hence, we explored a strategy of targeting <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> function to improve <z:chebi fb="105" ids="17234">glucose</z:chebi> and <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: <z:hpo ids='HP_0001427'>Mitochondrial</z:hpo> membrane potential (Deltapsim) is a marker of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> function; therefore, we set up a high-throughput screening assay of Deltapsim in L6 myotubes </plain></SENT>
<SENT sid="3" pm="."><plain>The effects of a selected lead compound were investigated in vitro and in vivo in relation to <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: A novel small-molecule compound, C1, was identified through this high-throughput screening </plain></SENT>
<SENT sid="5" pm="."><plain>C1 depolarized Deltapsim in L6 myotubes without cytotoxicity and led to increased cellular <z:chebi fb="47" ids="16027,28971">AMP</z:chebi>-to-ATP ratio, activation of <z:chebi fb="47" ids="16027,28971">AMP</z:chebi>-activated protein kinase (AMPK), and enhanced <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake </plain></SENT>
<SENT sid="6" pm="."><plain>It also stimulated the AMPK pathway in HepG2 cells, leading to decreased <z:chebi fb="23" ids="18059">lipid</z:chebi> content </plain></SENT>
<SENT sid="7" pm="."><plain>Intriguingly, C1 inhibited respiration in L6 myotubes but did not affect respiration in isolated muscle mitochondria, suggesting that it may depolarize Deltapsim indirectly by affecting the supply of <z:chebi fb="0" ids="15022,39144">electron donors</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> administration of C1 in C57BL/6J mice markedly increased fat oxidation and the phosphorylation of AMPK and <z:chebi fb="0" ids="15351">acetyl-CoA</z:chebi> carboxylase in the liver </plain></SENT>
<SENT sid="9" pm="."><plain>In diabetic db/db mice, <z:hpo ids='HP_0011010'>chronic</z:hpo> administration of C1 significantly reduced <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>, plasma fatty acids, <z:hpo ids='HP_0000833'>glucose intolerance</z:hpo>, and the <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels of <z:chebi fb="0" ids="18021">phosphoenolpyruvate</z:chebi> carboxykinase and <z:chebi fb="105" ids="17234">glucose</z:chebi>-6-phosphatase in the liver </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Our results demonstrate a novel small molecule that mildly depolarizes Deltapsim and is able to improve <z:chebi fb="105" ids="17234">glucose</z:chebi> and <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism to exert beneficial effects for <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>These findings suggest that compounds regulating <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> function may have therapeutic potential for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>